Key Events This Week
16 Mar: Downgrade to Sell rating announced amid valuation and technical concerns
19 Mar: Formation of Death Cross signals potential bearish trend
20 Mar: Stock rebounds sharply, gaining 6.47% but remains below week open
Apr 10
BSE+NSE Vol: 3.04 k

Parnax Lab Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 25 March 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 06 April 2026, providing investors with the most up-to-date view of the company’s performance and outlook.
Read full news article
16 Mar: Downgrade to Sell rating announced amid valuation and technical concerns
19 Mar: Formation of Death Cross signals potential bearish trend
20 Mar: Stock rebounds sharply, gaining 6.47% but remains below week open
23 Mar: Downgrade to Strong Sell amid bearish technicals and valuation concerns
25 Mar: New 52-week high at Rs.146.8
26 Mar: Upgrade to Hold as technicals and financials improve
27 Mar: Formation of Golden Cross signalling potential bullish breakout

The 50-day moving average has crossed above the 200-day moving average for Parnax Lab Ltd, signalling a golden cross on 27 Mar 2026. However, the stock declined 2.92% on the same day, while monthly momentum indicators remain mildly bearish. This juxtaposition of signals calls for a detailed examination of the technical and fundamental context to assess the reliability of the crossover.
Read full news article
Parnax Lab Ltd has seen its investment rating upgraded from Strong Sell to Hold, reflecting a notable improvement in its technical indicators and financial fundamentals. The upgrade, effective from 25 March 2026, is driven by a combination of enhanced technical trends, robust quarterly financial results, attractive valuation metrics, and a positive shift in market sentiment.
Read full news article
With a decisive gap-up opening and a 19.84% intraday surge, Parnax Lab Ltd soared to a fresh 52-week high of Rs 146.8 on 25 Mar 2026, extending its recent winning streak to two consecutive days and marking a notable 10.12% gain over this period.
Read full news article
Parnax Lab Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Sell to Strong Sell as of 23 March 2026. This shift reflects a deterioration in technical indicators despite some positive financial results, signalling caution for investors amid mixed signals across quality, valuation, financial trends, and technicals.
Read full news article
Parnax Lab Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has recently formed a Death Cross, a technical pattern where the 50-day moving average crosses below the 200-day moving average. This development is widely regarded as a bearish signal, indicating a potential deterioration in the stock’s medium to long-term trend and raising concerns about sustained weakness ahead.
Read full news article
Parnax Lab Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Hold to Sell as of 16 March 2026. This shift reflects a complex interplay of technical indicators, valuation metrics, financial trends, and quality assessments that collectively signal caution for investors despite the company’s strong long-term returns.
Read full news articlePlease find enclosed herewith the Compliance Certificate under regulation 74(5) of SEBI (DP) Regulation 2018.
The Trading Window for dealing in securities will be closed for all the Insiders Designated Persons and their Immediate Relatives w.e.f. 01st April 2026 and shall open 48 hours after the Audited Financial Results for the Quarter and Year ended March 30 2026 become generally available to he public.
Financial Results for the Quarter Ended December 31 2025.
No Upcoming Board Meetings
No Dividend history available
No Splits history available
No Bonus history available
No Rights history available